Royalty Pharma plc Proceeds from Long-Term Debt Issued
Royalty Pharma plc (RPRX) reported Proceeds from Long-Term Debt Issued of $1.47 billion for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2024-08-08
- Royalty Pharma plc proceeds from issuance of long-term debt for the quarter ending 2022-12-31 was $0.00.
- Royalty Pharma plc proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- Royalty Pharma plc proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $1.27B, a 78.25% decline year-over-year.
- Royalty Pharma plc proceeds from issuance of long-term debt for the quarter ending 2021-06-30 was $0.00.
- Royalty Pharma plc proceeds from issuance of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Royalty Pharma plc proceeds from issuance of long-term debt for fiscal 2021 was $1.27B, a 89.30% decline from fiscal 2020.
- Royalty Pharma plc proceeds from issuance of long-term debt for fiscal 2020 was $11.89B.
- Royalty Pharma plc proceeds from issuance of long-term debt for fiscal 2019 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-06-30 | $1.47B 10-Q · filed 2024-08-08 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $0.00 10-K · filed 2023-02-15 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.27B derived: sum of 2 quarters · filed 2023-02-15 | $1.27B derived: sum of 3 quarters · filed 2023-02-15 | $1.27B 10-K · filed 2023-02-15 |
| 2021-09-30 | $1.27B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.27B derived: sum of 2 quarters · filed 2022-11-08 | $1.27B 10-Q · filed 2022-11-08 | $1.27B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | $5.85B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | $5.85B derived: sum of 3 quarters · filed 2023-02-15 | $5.85B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $5.85B derived: sum of 2 quarters · filed 2023-02-15 | $5.85B derived: sum of 3 quarters · filed 2023-02-15 | $11.89B 10-K · filed 2023-02-15 |
| 2020-09-30 | $5.85B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.85B derived: sum of 2 quarters · filed 2021-11-10 | $11.89B 10-Q · filed 2021-11-10 | $11.89B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $6.04B 10-Q · filed 2021-08-11 | $6.04B derived: sum of 3 quarters · filed 2022-02-15 | $6.04B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $6.04B 10-Q · filed 2021-05-11 | $6.04B derived: sum of 2 quarters · filed 2022-02-15 | $6.04B derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |